Anemia, hiponatremia, hipoalbuminemia y déficit de vitamina K como factores de riesgo para osteoporosis / Anemia, hyponatremia, hypoalbuminemia and vitamin k deficit as risk factors for osteoporosis

La Osteoporosis es un síndrome altamente prevalente en la población mayor, tanto la que ha sufrido fracturas como la que no. Aunque con frecuencia se le relaciona con la menopausia, existen varios otros elementos involucrados en su génesis. Estos frecuentemente coexisten en diversa proporción y son, por lo general, oligosintomáticos o generan signosintomatología muy inespecífica. Esto hace que su diagnóstico y tratamiento se retrase u omita, aumentando el riesgo de caídas y fracturas, y dificultando los procesos de consolidación ósea. Aunque su nivel de evidencia es aún diverso, frecuentemente son hallados cuando se implementa su búsqueda en pacientes mayores fracturados. Por lo que, con independencia de si su relación con la osteoporosis es o no significativa, conviene buscarlos y manejarlos por el riesgo que constituyen por sí mismos. En esta revisión nos referiremos a cuatro de estas condiciones: Hipoalbuminemia, hiponatremia, anemia y deficiencia de vitamina K.

Osteoporosis is very prevalent in the aged and is seen in both those who have suffered fractures and those who have not. Frequently related to the menopause, there are other elements involved in its pathogenesis. These frequently co-exist and are, generally, oligo-symptomatic or have non-specific symptomatology. This causes delays or omissions in their diagnosis and treatment, thereby increasing the risk of falls and fractures and interfering with bone consolidation. Although their evidence levels are diverse, these factors are frequently to be found once directly looked for in the aged fracture patient. Therefore, even though their relation to the osteoporosis may not be significant, it is best to test for them and treat them for the risk they present. In this review we look at four of these conditions: hypoalbuminemia, hyponatremia, anemia and vitamin K deficiency

Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.

Patients with adenosine deaminase (ADA) deficiency exhibit spontaneous and partial clinical remission associated with somatic reversion of inherited mutations. We report a child with severe combined immunodeficiency (T-B- SCID) due to ADA deficiency diagnosed at the age of 1 month, whose lymphocyte counts including CD4+ and CD8+ T and NK cells began to improve after several months with normalization of ADA activity in Peripheral blood lymphocytes (PBL), as a result of somatic mosaicism caused by monoallelic reversion of the causative mutation in the ADA gene. He was not eligible for haematopoietic stem cell transplantation (HSCT) or gene therapy (GT); therefore he was placed on enzyme replacement therapy (ERT) with bovine PEG-ADA. The follow-up of metabolic and immunologic responses to ERT included gradual improvement in ADA activity in erythrocytes and transient expansion of most lymphocyte subsets, followed by gradual stabilization of CD4+ and CD8+ T (with naïve phenotype) and NK cells, and sustained expansion of TCRγδ+ T cells. This was accompanied by the disappearance of the revertant T cells as shown by DNA sequencing from PBL. Although the patient's clinical condition improved marginally, he later developed a germinal cell tumour and eventually died at the age of 67 months from sepsis. This case adds to our current knowledge of spontaneous reversion of mutations in ADA deficiency and shows that the effects of the ERT may vary among these patients, suggesting that it could depend on the cell and type in which the somatic mosaicism is established upon reversion.

Semiquantification of hypothalamic GH-releasing hormone output in women: evidence for sexual dimorphism in the mechanism of the somatopause.

The neuroendocrine mechanisms underlying the decline of GH with aging (somatopause) are uncertain. We recently found that the age-dependent diminution of the hypothalamic GH-releasing hormone (GHRH) output contributes to the somatopause in men. As the regulatory mechanisms of GH secretion are sexually dimorphic, we assessed the suppressibility of spontaneous and GHRH-stimulated GH secretion by graded doses of a specific competitive GHRH receptor antagonist in nine young (20-27 yr old) and eight elderly (65-77 yr old) healthy nonobese women to semiquantify hypothalamic GHRH output. Nocturnal mean GH was lower in elderly women (2.2 +/- 0.4 vs. 0.9 +/- 0.2 microg/liter; P = 0.01). Graded boluses of GHRH-44 resulted in similar GH responses in both populations (P = 0.28). Graded infusions of GHRH antagonist inhibited in a dose-dependent manner the GH responses to GHRH in both groups (P = 0.0001-0.04). The dose-inhibition curve for the lowest GHRH bolus dose was shifted to the left compared with the highest one (P = 0.04). However, the dose-inhibition curves for spontaneous GH secretion were not different in young and elderly women (P = 0.50). Thus, the female somatopause is not associated with a measurable decrease in hypothalamic GHRH output. When the dose-inhibition curves for young men and young women were compared, the latter was shifted to the left (P = 0.009), suggesting that the somatotropic system in women operates with less GHRH. We conclude that the contribution of endogenous GHRH to the maintenance of GH secretion and the neuroendocrine mechanisms of somatopause in humans are sexually dimorphic.

Bilateral symmetrical basal ganglia infarction after intravenous use of cocaine and heroin.

A case is reported of a young man who developed bilateral symmetrical basal ganglia infarcts after intravenous use of cocaine and heroin. Ischemic infarcts of the brain are a known complication of to cocaine use, alone or in combination with heroin (speed balling). This symmetrical occurrence of infarction, however, is unusual and has not been reported after cocaine use.

Pituitary disorders. Drug treatment options.

Pituitary diseases are relatively common entities in the general population. They include pituitary adenomas and hypopituitarism. Pituitary tumours can cause symptoms of mass effect and hormonal hypersecretion that can be reversed with surgical resection or debulking of the adenoma, radiotherapy, or medical treatment. Transsphenoidal adenomectomy is the treatment of choice for acromegaly, Cushing's disease, gonadotropin-secreting tumours; and thyrotropin (TSH)-secreting adenomas. Pituitary irradiation and medical therapy are secondary options. Conversely, medical treatment is the primary choice for prolactinomas. Dopamine agonists are very effective in the treatment of prolactin (PRL)-secreting tumours, with rates of control as high as 80 to 90% for microprolactinomas (< 10 mm) and 60 to 75% for macroprolactinomas (> or = 10 mm). Somatostatin analogues have also shown efficacy in patients with acromegaly who have not responded to surgery or in patients with TSH-secreting adenomas who have not improved with surgery and radiotherapy. In patients with Cushing's disease, who are not cured surgically or who relapse after pituitary adenomectomy and irradiation, steroidogenic inhibitors can be an efficient method of controlling the hypercortisolism. Pituitary insufficiency is the partial or complete loss of the anterior hypophyseal function, which is due to hypothalamic or pituitary disease. Although the classic sequence of loss of pituitary secretion is growth hormone (GH), gonadotropins, TSH, and corticotropin (ACTH), the order to begin the replacement therapy of the deficient hormone(s) is cortisol, thyroxine, androgens/estrogens and, if necessary, GH. There are multiple preparations that can be used to achieve clinical and biochemical improvement. In general, the hormone replacement therapy is lifelong.

Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.

Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medical treatment with dopamine agonists is the therapy of choice for macroprolactinomas (> or = 10 mm). Withdrawal of bromocriptine after weeks or months of uninterrupted therapy has been associated with rapid tumor re-expansion as evidenced by x-ray and CT scanning of the pituitary region. We report a patient with a giant macroprolactinoma who had a dramatic response to bromocriptine (tumor volume shrinkage of 53% within a month) but rapid re-expansion to its original dimensions one week after discontinuation of bromocriptine. To our knowledge, this is the first time that the rapid shrinkage/re-expansion of a macroprolactinoma has been documented with serial MRI scans.

Pergolide as primary therapy for macroprolactinomas.

The objective of this study is to determine whether pergolide therapy is an effective modality for the de novo treatment of patients with macroprolactinomas. Twenty-two consecutive patients with macroprolactinomas were included in the study and followed prospectively. These included 16 men and 6 women in whom pregnancy was not of concern. Pergolide was administered once or twice a day depending on the patient's preference. Ten patients received 0.1 mg daily as a maintenance regimen and in the others the daily dose ranged from 0.05 to 0.5 mg. Eight patients reported minor but tolerable side effects. One patient had to be switched to cabergoline because of intolerable nausea. After a mean of 12 months (range, 3-36), mean PRL levels declined from 3,135 ng/ml (range, 126-31,513) to 50 ng/ml (3-573), representing a mean PRL suppression of 88% (range, 0-99). PRL levels became normal in 15 patients and decreased to 25-40 ng/ml in 3 others. The mean tumor volume shrinkage was 25% or greater in 19 patients (86%), 50% or greater in 17 patients (77%), and 75% or greater in 10 patients (45%). Visual abnormalities were reversible after pergolide therapy in all but 1 of 12 patients with initially abnormal formal visual testing. Two out of 4 premenopausal women did not normalize PRL levels and had persistent oligomenorrhea. Testosterone was low in 14 men at presentation and normalized in 3 with pergolide therapy. We conclude that pergolide is a safe, inexpensive, and generally well-tolerated dopamine agonist for the treatment of macroprolactinomas in men and women in whom pregnancy is not of concern. In these specific populations, pergolide may become the first-line therapy for treatment of macroprolactinomas.

[Clinical characteristics of Meckel's diverticulum in a population of children]. / Características clínicas del divertículo de Meckel en una población infantil.

A descriptive and retrospective study was realized during a period of eleven years from January 1983 to December 1993. There were found 101 cases, of which 75.25% were Meckel's diverticulum complicated. The incidence found was of 1.2%. The 89.5% of the complicated cases were less than 10 years old, and the 47.4% were less than 2 years old. The most frequent symptoms were: abdominal pain (68.4%), vomiting (68.4%), fever (47.3%), and abdominal distention (39.4%). The congenital anomalies presented in 17.8%, were: intestinal malrotation, congenital bands, hernia inguinal and omphalocele. The most common complications were: intestinal obstruction (47.4%), diverticulitis (19.7%), lower digestive hemorrhage (15.8%), and intestinal perforation (14.5%) of the cases. The heterotopic tissue was present in 20.7% cases. In our Institute, the age's group less than 2 years old, presented more complicated cases (p < 0.01). The intestinal obstruction was the most common picture (p < 0.001). The lower gastrointestinal hemorrhage was the second complication in patients less than 2 years old (p < 0.05). We found a strong association with other congenital anomalies.

New temperate bacteriophage for Bacillus subtilis, rho 11.

A new temperate bacteriophage, rho11, isolated by J. Hoch, has been characterized. This new phage is very similar to the temperate phage phi3T in size (380 nm), host range, homoimmunity, DNA buoyant density (1.694 g/ml), antigenicity, and molecular weight (around 6.0 X 10(7)) as determined in gels. Like phi3T, rho11 converts thymine auxotrophs to prototrophy at high frequency (250 out of 250 tested). Phage rho11 differs from phi3T in plaque morphology and in the endonuclease R-EcoRI digest pattern. Sixteen of the 20 rho11 DNA fragments have migration patterns corresponding to those of the 21 fragments of phi3T. The close similarities yet clear differences between these phages suggest that the two phages have a common ancestor.